Unpartnered Products: Potential Biopharma Game Changers
This article was originally published in Start Up
Executive Summary
As the pharmaceutical landscape continues to consolidate through acquisitions and partnerships, the untapped market of unpartnered products represents a potential multibillion-dollar opportunity. This analysis, derived from Informa’s Medtrack pharmaceutical intelligence and deals database, delves into the private company pipeline landscape, examining unpartnered candidates by therapy area and phase of development.
You may also be interested in...
Up-Front Deal Economics May Not Match Drugs’ Likelihood Of Approval
In earlier development phases, most of the therapeutic classes with higher approval rates tend on average to have the larger up-front alliance payments. But in Phase III, licensees are paying top dollar for candidates in areas with the lowest likelihoods of approval.
Deals Shaping The Medical Industry, February 2019
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2019.
Deals Shaping The Medical Industry, January 2019
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2018.